Gland Pharma Limited announced the successful conclusion of the US FDA’s Good Manufacturing Practices (GMP) inspection at its Pashamylaram facility in Hyderabad.
The inspection, which took place between July 25 and August 2, 2024, has been officially closed, with the company receiving the Establishment Inspection Report (EIR) from the US FDA. This marks a positive outcome, reflecting the company’s adherence to stringent quality standards.
In the exchange filing, the company shared, “The Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 25th July, 2024 and 02nd August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.”
